MESO Mesoblast limited.
5,276
$6.95
$0.4119
(5.60%)
| Watchers | 5,276 |
| 52-Wk Low | $1.61 |
| 52-Wk High | $10.24 |
| Market Cap | $839.95M |
| Volume | 114,810.00 |
| 52-Wk High | $10.24 |
| 52-Wk Low | $1.61 |
Mesoblast (NASDAQ:MESO) Sees Strong Trading VolumeTicker Report • about 1 month ago
Mesoblast Limited (NASDAQ:MESO - Get Free Report) shares saw unusually-high trading volume on Monday . Approximately 5,883,669 shares were traded during mid-day trading, an increase of 210% from the...
Share to Feed
Mesoblast Limited (NASDAQ:MESO - Get Free Report)'s share price was up 6.6% on Tuesday . The company traded as high as $6.48 and last traded at $6.48. Approximately 1,516,520 shares changed hands...
Mesoblast Limited (NASDAQ:MESO - Get Free Report)'s share price gapped up prior to trading on Thursday . The stock had previously closed at $3.49, but opened at $4.46. Mesoblast shares last traded at...
In this piece, we will take a look at the ten best long term ASX stocks to invest in. If you want to skip our overview of the Australian stock market, then you can take a look at the 5 Best Long Term...
iBio, Mesoblast, Kodiak Sciences among healthcare movers...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that U.S. FDA has...
NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has received firm...
NEW YORK, March 10, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that U.S. FDA...
StockNews.com upgraded shares of Mesoblast (NASDAQ:MESO Free Report) from a sell rating to a hold rating in a research report report published on Monday morning. Separately, Cantor Fitzgerald...